BFGIX
Price
$65.83
Change
+$3.11 (+4.96%)
Updated
Jun 12 closing price
Net Assets
6B
RPMGX
Price
$99.22
Change
+$0.52 (+0.53%)
Updated
Jun 12 closing price
Net Assets
22.57B
Interact to see
Advertisement

BFGIX vs RPMGX

Header iconBFGIX vs RPMGX Comparison
Open Charts BFGIX vs RPMGXBanner chart's image
BFGIX vs RPMGX Comparison Chart in %
View a ticker or compare two or three
VS
BFGIX vs. RPMGX commentary
Jun 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BFGIX is a Buy and RPMGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RPMGX has more cash in the bank: 22.6B vs. BFGIX (6B). BFGIX (0.00) and RPMGX (0.00) have matching dividends . BFGIX was incepted earlier than RPMGX: BFGIX (17 years) vs RPMGX (34 years). BFGIX (1.05) is less costly to investors than RPMGX (0.77). RPMGX is a more actively managed with annual turnover of: 31.50 vs. BFGIX (8.00). RPMGX has a lower initial minimum investment than BFGIX: RPMGX (2500) vs BFGIX (1000000). BFGIX annual gain was more profitable for investors over the last year : 29.87 vs. RPMGX (0.10). BFGIX return over 5 years is better than : 47.87 vs. RPMGX (-18.36).
BFGIXRPMGXBFGIX / RPMGX
Total Expense Ratio1.050.77136%
Annual Report Gross Expense Ratio1.050.77136%
Fund Existence17 years34 years-
Gain YTD8.8642.036435%
Front LoadN/AN/A-
Min. Initial Investment1000000250040,000%
Min. Initial Investment IRAN/AN/A-
Net Assets6B22.6B27%
Annual Yield % from dividends0.000.00-
Returns for 1 year29.870.1029,605%
Returns for 3 years82.711.097,590%
Returns for 5 years47.87-18.36-261%
Returns for 10 years401.8534.601,162%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AKTS21.932.47
+12.69%
Aktis Oncology Inc
ACLS180.126.55
+3.77%
Axcelis Technologies
MMM158.320.41
+0.26%
3M Company
PROF6.62-0.02
-0.38%
Profound Medical Corp
NEUP4.37-0.12
-2.67%
Neuphoria Therapeutics Inc